Treatments

An emerging treatment option for men with recurring prostate cancer after radiation therapy

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Prostate cancer is often a multifocal disease, meaning that several tumors can be present in different parts of gland at the same time. Not all of these tumors are equally problematic, however. And it’s increasingly thought that the tumor with the most aggressive features — called the index lesion — dictates how a man’s cancer […]

Hormonal therapies for advanced prostate cancer linked to a higher risk of falls and fractures

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Falls rank among the top causes of death and injuries among the elderly, and the risk increases significantly in older people being treated for cancer. Now, investigators are reporting that a newer class of drugs for advanced prostate cancer is associated with a significant increase in fall risk. Called androgen receptor inhibitors, or ARIs, these […]

The sequence of hormonal therapy and radiation affects outcomes in men treated for prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

A common treatment for men with intermediate-risk prostate cancer is to combine radiation with drugs that block testosterone — a hormone that makes the tumors grow faster. (This type of treatment is also called androgen deprivation therapy, or ADT). New research is suggesting the sequence of these treatments may be crucially important. Dr. Dan Spratt, […]

Hormonal treatments for prostate cancer may prevent or limit COVID-19 symptoms

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men have roughly twice the risk of developing severe disease and dying from COVID-19 than women. Scientists say this is in part because women mount stronger immune reactions to the disease’s microbial cause: the infamous coronavirus called SARS-CoV-2. Now research with prostate cancer patients points to another possible explanation, which is that the male sex […]

Hormonal treatments for prostate cancer are often given late

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men with advanced prostate cancer are typically treated with drugs that cause testosterone levels to plummet. Testosterone is a hormone that fuels growing prostate tumors, so ideally this type of treatment, which is called androgen deprivation therapy (ADT), or hormonal therapy, will stall the disease in its tracks. For that to happen, ADT has to […]

A new hormonal therapy for prostate cancer is under expedited FDA review

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

In June, the US Food and Drug Administration (FDA) launched an accelerated review of a promising new drug for advanced prostate cancer. Called relugolix, it suppresses testosterone and other hormones that speed the cancer’s growth. If approved, this new type of hormonal therapy is expected to set a new standard of care for the disease. […]

New drugs approved for advanced BRCA-positive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Defective BRCA genes are well known for their ability to cause breast and ovarian cancers in women. But these same gene defects are also strong risk factors for aggressive prostate cancer in men. About 10% of men with metastatic prostate cancer — meaning cancer that is spreading away from the prostate — test positive for […]

New radiation therapies keep advanced prostate cancer in check

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Treatments for prostate cancer are always evolving, and now research is pointing to new ways of treating a cancer that has just begun to spread, or metastasize, after initial surgery or radiation. Doctors usually give hormonal therapies in these cases to block testosterone, which is a hormone that makes the cancer grow faster. But newer […]

New study compares long-term side effects from different prostate cancer treatments

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal […]

African American and white men who receive comparable treatments for prostate cancer have similar survival

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Last year, we reported on two studies showing that African American men respond at least as well as white men to prostate cancer treatments given in clinical trials. Nationally, African Americans with prostate cancer are more than twice as likely to die of the disease as their white counterparts, and that has fueled speculation that […]